USPSTF on PSA screening … a current update …

The U.S. Preventive Services Task Force (USPSTF) has just issued its “Guide to Clinical Preventive Services” for 2014. The publication (which is available on line) includes summary information about screening for prostate cancer. … READ MORE …

Maybe this time … a real answer to the value of PSA screening?

We have frequently referred to an ongoing trial in the UK known as the ProtecT trial. That trial is comparing the effectiveness and safety of surgery, radiation therapy, active surveillance as treatments for well-characterized men diagnosed with localized prostate cancer … but there is something else important we hadn’t realized … … READ MORE …

“A plea for individualized prostate cancer screening”

For some years, Vickers, Lilja, and their associates have been arguing that baseline PSA level is able to predict long-term risk for prostate cancer, and now a new paper in European Urology seems to provide support for this argument and a practical clinical strategy for its application. … READ MORE …

Old and newer tests and risks for prostate cancer; can you avoid inappropriate biopsy?

We now have five approved tests that can (at least in theory) help a man — and his doctors — to decide whether he is at sufficient risk for clinically significant prostate cancer that he should go get a biopsy. But how good are they really? … READ MORE …

Shared and emotion-free decision-making with respect to PSA-based screening

The following is (slightly edited) report by Jeffrey J. Tomaszewski, MD, on behalf of UroToday.com, of a state-of-the-art lecture by David Penson, MD, presented at the annual meeting of the American Urological Association (AUA) in Orlando. We hope that UroToday will forgive us for this direct “theft”, but the topic is one of enormous relevance to the patient community. … READ MORE …

Evaluation of the real utility of new biomarkers for prostate cancer risk

There is a fascinating comment by Kattan scheduled for publication in a forthcoming issue of the new journal Urology Practice. It makes a truly critical point about whether any of the new biomarkers are actually adding significantly to what we know about how to assess risk for prostate cancer. … READ MORE …

New NCCN guidelines on prostate cancer are not an all-around success!

Alas, the latest revisions to the National Comprehensive Cancer Network (NCCN) guidelines on early detection of prostate cancer seem to have instigated more furore than they have clarity (although the original premise behind them may have been well intentioned). … READ MORE …

“Five golden rules” for prostate cancer screening and treatment today

In a very simple and straightforward article in European Urology, Vickers et al. have clearly laid out a series of five “golden rules” that, in their opinion, all physicians should be following today when they are testing men for risk of prostate cancer through the use of the PSA test. … READ MORE …

New prostate cancer “vaccine” in Phase II trial prior to ADT

According to a media release we saw this morning, a company called Madison Vaccines has started a Phase II clinical trial of a new form of immunotherapy for treatment of men with non-metastatic prostate cancer and rising PSA levels prior to any treatment with androgen deprivation therapy (ADT). … READ MORE …

Criteria for active surveillance are gradually improving

Being diagnosed with low-risk prostate cancer is a good reason to consider management under active surveillance (as opposed to immediate, early intervention) … but active surveillance won’t be right for every low-risk patient! … READ MORE …

Poor guidance from the AAFP, badly interpreted by the media

According to a recent recommendation from the American Academy of Family Physicians in association with the Choosing Wisely campaign. primary care physicians are being advised as follows: … READ MORE …

New prospective study supports baseline PSA testing for men in 40s

According to a newly published, prospective study in the Journal of Urology, a research team at the Mayo Clinic has confirmed prior reports (based on retrospective data) that a baseline PSA in men aged between 40 and 49 years can be used to categorize men into low and higher prostate cancer risk groups. … READ MORE …

Urologists’ and radiation oncologists’ opinions on use of PSA test to screen for prostate cancer

A new study has provided data on the opinions of a random sample of 1,366 radiation oncologists and urologists with regard to the appropriate role of the PSA test in screening for prostate cancer (since the recommendation of a D grade for this test as a screening mechanism by the U.S. Preventive Services Task Force (USPSTF). … READ MORE …

Dr. David Agus on CBS’s “Morning Rounds”

So the role of prostate cancer screening got discussed on the CBS television program “Morning Rounds” on Saturday, by Dr. David Agus (a well-known urologic oncologist) and others. The context was the recent data on the “overuse” of the PSA test in men of 75+ years of age. … READ MORE …

Cost and prevalence of PSA testing in Medicare patients > 70 years old

A recent article in Cancer has stimulated media coverage of the appropriate role of PSA testing in men of > 70 years of age and costs covered by Medicare for PSA tests in men over this age. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,115 other followers